Lidocaine for Tinnitus: Efficacy Review

Approximately 15% of people globally experience tinnitus. For decades, clinicians have explored the sodium channel blocker lidocaine as a potential treatment, based on its ability to quiet abnormal neural activity. A new systematic review and meta-analysis synthesizes the best available evidence on whether this common local anesthetic can actually reduce tinnitus symptoms.

How Researchers Compiled the Evidence

To answer the question, the review team searched six major scientific databases, including PubMed and Cochrane, for all relevant studies published up to November 2025. They focused exclusively on randomized controlled trials, the gold standard for testing medical interventions. Their final analysis included 12 studies with a total of 550 participants. The quality of each study was critically appraised using the Cochrane Risk of Bias 2 tool. Four studies were rated as having a low risk of bias, while eight raised some concerns, often related to how participants were assigned to treatment groups or how outcomes were measured.

Overall Severity Unchanged, But Specific Symptoms May Shift

The meta-analysis produced clear headline results. When data from studies using the Tinnitus Handicap Inventory (THI) were pooled, lidocaine showed a non-significant effect, with a mean effect size of 0.358. The confidence interval crossed zero (95% CI: -0.092 to 0.809), meaning the result could be due to chance. The statistical significance was p = 0.119. Similarly, for studies measuring tinnitus intensity on a Visual Analog Scale (VAS), the effect was also non-significant (effect size 0.145, 95% CI: -0.398 to 0.687, p = 0.601).

However, looking beyond these composite scores tells a more nuanced story. Several individual studies reported that intravenous or intratympanic (injected into the middle ear) lidocaine could temporarily alter the character of tinnitus. Patients described reductions in tinnitus pitch, perceived loudness, and the distress associated with the sound. Some studies even noted incidental improvements in hearing thresholds. This suggests lidocaine may affect the auditory system, but not in a consistent or sustained way that reliably improves a person’s overall reported handicap.

Why the Evidence Is So Hard to Interpret

The review identified major sources of heterogeneity that make a definitive conclusion impossible. The routes of administration varied widely—including intravenous, intratympanic, and topical applications—each with different pharmacokinetics and risks. Treatment protocols (dose, frequency) were not standardized across studies. The participant populations also differed, including people with sudden sensorineural hearing loss versus chronic idiopathic tinnitus.

This inconsistency is reflected in the high I² statistics of 77% and 79% for the THI and VAS analyses, indicating substantial variation between study results beyond chance. In essence, the signal of lidocaine’s effect is drowned out by the noise of different study methods. This heterogeneity is a common challenge in tinnitus research, where subjective experience and diverse underlying causes complicate treatment trials.

Practical Implications for Patients and Clinicians

For individuals seeking relief from tinnitus, this review indicates that lidocaine is not a proven or reliable treatment. The lack of a significant effect on validated severity scales like the THI is a critical finding. While some people might experience temporary changes in their tinnitus sound during a clinical trial, these effects do not consistently translate to a meaningful reduction in the life impact of the condition.

The transient nature of any potential benefit is another major limitation. Lidocaine’s pharmacological action is short-lived, making it unsuitable for managing a chronic condition like tinnitus. Furthermore, intravenous administration carries risks and requires clinical supervision, while intratympanic injection is an invasive procedure. Given these factors and the inconclusive evidence, lidocaine cannot be recommended for standard clinical use in tinnitus management.

Current approaches focus more on habituation and managing the reaction to tinnitus, such as with Cognitive Behavioral Therapy (CBT), or on other forms of neuromodulation. The search for an effective pharmaceutical intervention continues, but lidocaine, based on this comprehensive review, is not the answer. Future research must employ more standardized protocols and better-defined patient subgroups to identify if any specific population might benefit.

Connections to Broader Hearing Health Challenges

The investigation into lidocaine touches on a core theme in auditory neuroscience: the quest to calm hyperactive neural networks. This is relevant not only to tinnitus but also to conditions like hyperacusis and misophonia, where the brain’s response to sound is pathologically heightened. While lidocaine targets sodium channels, other research explores different mechanisms for quieting this excitability.

Understanding these shared pathways is key to developing better treatments. For instance, the neural plasticity involved in tinnitus has parallels in other sensory processing disorders. The frustration of an inconclusive treatment like lidocaine underscores the complexity of the auditory brain and the need for personalized, multi-faceted approaches. It also highlights why researchers are exploring strategies like the “Judo Strategy” for AI in hearing health, which aims to use the brain’s own adaptive processes for therapeutic benefit. Furthermore, the emotional distress component of tinnitus, which lidocaine did not reliably alleviate, is a central feature in conditions like misophonia, pointing to another critical area for intervention.

For now, the evidence suggests that managing the stress and sleep disruption that often accompany chronic tinnitus may offer more consistent benefit. Improving sleep, for example, can lower general nervous system arousal, potentially reducing the perceived burden of tinnitus, a connection supported by research into sleep hygiene.

Source: The evidence presented in this article is based on the systematic review “Effects of lidocaine on tinnitus symptoms: A systematic review and meta-analysis” by Anas Alashram et al. (DOI: 10.1186/s43163-026-01130-3).